Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Wick

Showing results (161-170 of 170) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 170 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015Mary B Daly, Robert Pilarski, Jennifer E Axilbund, et al.
Human Genetics|March 28, 2024
Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome dataAlejandro Ferrer, Patrick Duffy, Rory J Olson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
Cancer Discovery|July 12, 2018
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast CancerXiaoling Puyang, Craig Furman, Guo Zhu Zheng, et al.
Mayo Clinic Proceedings|December 3, 2024
Mayo Clinic Tapestry Study: A Large-Scale Decentralized Whole Exome Sequencing Study for Clinical Practice, Research Discovery, and Genomic EducationLorelei A Bandel, Robert A Vierkant, Teresa M Kruisselbrink, et al.
American Journal of Human Genetics|March 9, 2019
De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and DyskinesiasKatherine L Helbig, Robert J Lauerer, Jacqueline C Bahr, et al.
American Journal of Human Genetics|October 23, 2018
De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and DyskinesiasKatherine L Helbig, Robert J Lauerer, Jacqueline C Bahr, et al.
Pageof 17

Showing results (161-170 of 170) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 170 results.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015Mary B Daly, Robert Pilarski, Jennifer E Axilbund, et al.
Human Genetics|March 28, 2024
Semiautomated approach focused on new genomic information results in time and effort-efficient reannotation of negative exome dataAlejandro Ferrer, Patrick Duffy, Rory J Olson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026Heather H Cheng, Veda N Giri, Michael Goggins, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 19, 2023
NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024Mary B Daly, Tuya Pal, Kara N Maxwell, et al.
Cancer Discovery|July 12, 2018
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERα<sup>WT</sup> and ERα<sup>MUT</sup> Breast CancerXiaoling Puyang, Craig Furman, Guo Zhu Zheng, et al.
Mayo Clinic Proceedings|December 3, 2024
Mayo Clinic Tapestry Study: A Large-Scale Decentralized Whole Exome Sequencing Study for Clinical Practice, Research Discovery, and Genomic EducationLorelei A Bandel, Robert A Vierkant, Teresa M Kruisselbrink, et al.
American Journal of Human Genetics|March 9, 2019
De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and DyskinesiasKatherine L Helbig, Robert J Lauerer, Jacqueline C Bahr, et al.
American Journal of Human Genetics|October 23, 2018
De Novo Pathogenic Variants in CACNA1E Cause Developmental and Epileptic Encephalopathy with Contractures, Macrocephaly, and DyskinesiasKatherine L Helbig, Robert J Lauerer, Jacqueline C Bahr, et al.
Pageof 17